Theory Paper IIDrNB Cardiology – Theory Notes
CARDIAC AMYLOIDOSIS; CURRENT STATUS OF DIAGNOSIS
ITHE DIAGNOSTIC PARADIGM SHIFT (GILLMORE ALGORITHM / ESC 2021-2023 / ACC 2023)
- Two Dominant Clinical Subtypes (>95% of All Cardiac Amyloidosis):
- Immunoglobulin Light-Chain (AL) Amyloidosis: Clonal plasma cell dyscrasia secreting misfolded lambda (75–80%) or kappa (20–25%) immunoglobulin light chains; medical emergency with <6-month untreated survival if severe cardiac involvement is present.
- Transthyretin (ATTR) Amyloidosis: Misfolding of hepatic transthyretin (prealbumin) tetramers into amyloid fibrils, divided into Wild-Type ATTR (ATTRwt, formerly “senile systemic amyloidosis”) (predominantly older men >=65 yr) and Hereditary/Variant ATTR (ATTRv) (autosomal dominant TTR gene mutations such as Val122Ile [p.Val142Ile], Thr60Ala, and Val30Met).
- The Non-Invasive Diagnostic Revolution: Based on the landmark validation by Gillmore et al. (Circulation 2016), ATTR Cardiac Amyloidosis can be diagnosed with ~100 percent specificity and positive predictive value WITHOUT an invasive biopsy when Grade 2 or 3 myocardial uptake on bone-avid radiotracer scintigraphy is combined with complete absence of a monoclonal protein in serum and urine.
IIEXTRACARDIAC AND CARDIOVASCULAR “RED FLAGS” (WHEN TO SUSPECT AMYLOIDOSIS)
- Orthopedic and Soft-Tissue Red Flags (Frequently Precede Heart Failure by 5 to 10 Years in ATTR):
- Bilateral Carpal Tunnel Syndrome (most common early sign, present in ~50% of ATTRwt 5 to 10 years before cardiac diagnosis).
- Lumbar Spinal Canal Stenosis (ligamentum flavum amyloid infiltration).
- Spontaneous Distal Biceps Tendon Rupture (“Popeye Sign”) (present in ~33% of ATTRwt) and trigger finger / total hip or knee arthroplasty.
- Pathognomonic Mucocutaneous Signs of AL Amyloidosis: Macroglossia (tongue enlargement with lateral dental indentations) and periorbital purpura (“raccoon eyes”) after minor coughing/Valsalva, alongside nephrotic-range proteinuria and hepatomegaly.
- Neurological Red Flags: Sensorimotor peripheral polyneuropathy (ascending numbness/pain, classic in ATTRv and AL) and dysautonomia (profound orthostatic hypotension, postprandial diarrhea/constipation, erectile dysfunction, and urinary retention).
- Cardiovascular Phenotypic Clues:
- Voltage-to-Mass Discordance: Marked concentric biventricular wall thickening (>=12 to 14 mm) on echocardiography paired with low QRS voltage (all limb leads <=5 mm or precordial leads <=10 mm; present in ~50–60% of AL and ~25–30% of ATTR) or absence of expected LVH voltage with a “pseudo-infarction” QS pattern in anterior/inferior leads (present in 50 to 70% despite clean coronary arteries).
- “Auto-Cure” of Hypertension and GDMT Intolerance: A previously hypertensive patient whose blood pressure spontaneously normalizes or who develops severe hypotension/bradycardia on low doses of ACEi/ARB/ARNI or Beta-Blockers.
- Specific High-Prevalence Cohorts: 13 to 16 percent of elderly patients undergoing TAVR for severe Aortic Stenosis (especially Low-Flow, Low-Gradient severe AS), 13 to 17 percent of hospitalized HFpEF patients with LV wall thickness >=12 mm, and middle-aged/older adults with unexplained Complete Heart Block or Atrial Fibrillation.
IIISTEP 1: MANDATORY LABORATORY EXCLUSION OF AL AMYLOIDOSIS (ALL THREE TESTS REQUIRED)
- The Cardinal Rule: Because up to 20 to 30 percent of patients with AL Cardiac Amyloidosis can also show false-positive Grade 1, 2, or 3 myocardial uptake on Tc-99m PYP/DPD bone scintigraphy, a bone scan can NEVER be interpreted in isolation without simultaneously ordering the Monoclonal Protein Triad:
- Serum Free Light Chain (sFLC) Assay (Quantitative Kappa and Lambda Free Light Chains + Kappa/Lambda Ratio): Normal serum kappa/lambda ratio is 0.26 to 1.65 (extended to 0.37 to 3.10 in severe CKD / eGFR <30 mL/min because free light chains are renally cleared).
- Serum Protein Electrophoresis with Immunofixation (SPIE / SIFE).
- 24-Hour (or Spot) Urine Protein Electrophoresis with Immunofixation (UPIE / UIFE).
- Crucial Exam Trap: Standard Serum Protein Electrophoresis (SPEP) alone is insufficient (sensitivity only ~50 to 70% in AL because the monoclonal light-chain spike is often too small to form an M-band on standard SPEP); combining sFLC + SIFE + UIFE achieves >99 percent sensitivity for detecting AL Amyloidosis.
IVSTEP 2: MULTIMODALITY ECHOCARDIOGRAPHY AND CARDIAC MRI
- Transthoracic Echocardiography and 2D Speckle-Tracking Strain:
- Structural Hallmarks: Concentric LV and RV free-wall thickening (>=12 mm; RV free wall >5 mm), thickened interatrial septum and AV valve leaflets, bi-atrial dilation, small pericardial effusion, and Grade III restrictive mitral inflow (E/A >2.0, deceleration time <150 ms, e’ <5 cm/s, E/e’ >15).
- The “Cherry-on-Top” Apical Sparing Bull’s-Eye Pattern: Profound impairment of longitudinal strain in the basal and mid-ventricular segments with preserved strain at the LV apex (Relative Apical Longitudinal Strain ratio = [Average Apical LS] / [Average Basal LS + Average Mid LS] >= 1.0).
- Cardiac Magnetic Resonance (CMR — Reference Tissue Characterization):
- Late Gadolinium Enhancement (LGE) and Nulling Kinetics: Diffuse circumferential subendocardial or transmural LGE (often involving the right ventricle and both atria) accompanied by abnormal gadolinium inversion-time (TI) kinetics—on the TI scout sequence, the amyloid-infiltrated myocardium reaches the null point (turns black) BEFORE or simultaneously with the LV blood pool.
- Parametric Mapping: Markedly elevated Native T1 (>1,100 to 1,150 ms at 1.5T) and massively expanded Extracellular Volume (ECV >= 40 percent, often 50 to 70 percent)—the highest ECV values seen in any cardiomyopathy.
| Diagnostic Step / Modality | Specific Finding / Cut-off | Clinical Action / Interpretation |
|---|---|---|
| Step 1: Monoclonal Screen | sFLC (Kappa/Lambda ratio) + SIFE + UIFE | If ANY test is abnormal -> Non-invasive pathway STOPS; urgent Hematology + Tissue Biopsy with Mass Spectrometry |
| Step 2: Echo & CMR | Wall thickness >=12 mm + Apical Sparing GLS (“Cherry-on-Top”); CMR subendocardial/transmural LGE, abnormal TI nulling, & ECV >=40% | Confirms cardiac amyloid phenotype; does not reliably differentiate AL from ATTR (requires Step 1 + Step 3) |
| Step 3: Tc-99m PYP / DPD / HMDP Bone Scintigraphy + SPECT | Perugini Grade 2 or 3 (Heart/Contralateral Lung [H/CL] ratio >=1.5 at 1h or >=1.3 at 3h) + Negative sFLC/SIFE/UIFE | 100% Specificity & PPV for ATTR Cardiac Amyloidosis (No biopsy required) |
| Step 4: TTR Gene Sequencing | Sanger / NGS sequencing of the TTR gene | Class I Mandatory in all confirmed ATTR-CM to distinguish ATTRwt from ATTRv (cascade family screening) |
VSTEP 3: BONE-AVID RADIOTRACER SCINTIGRAPHY (THE NON-INVASIVE ATTR CONFIRMATION)
- Radiotracers: Technetium-99m Pyrophosphate (Tc-99m PYP), Tc-99m 3,3-diphosphono-1,2-propanodicarboxylic acid (Tc-99m DPD), or Tc-99m Hydroxymethylene Diphosphonate (Tc-99m HMDP). (Crucial Exam Trap: Tc-99m MDP [Methylene Diphosphonate], the standard orthopedic bone scan tracer used in many general radiology departments, has low sensitivity for cardiac ATTR and must NOT be used.)
- Perugini Visual Grading Scale (at 1 or 3 Hours Post-Injection) + Mandatory Tomographic SPECT:
- Grade 0: No myocardial uptake and normal bone/rib uptake.
- Grade 1: Myocardial uptake less than rib uptake.
- Grade 2: Myocardial uptake equal to rib uptake.
- Grade 3: Myocardial uptake greater than rib uptake with mild or absent rib uptake.
- Mandatory SPECT Confirmation: Planar Heart-to-Contralateral Lung (H/CL >= 1.5 at 1 hour or >= 1.3 at 3 hours) ratios alone can be falsely positive due to residual radiotracer in the LV blood pool (especially in low-output heart failure or CKD); therefore, 3D SPECT/CT imaging is mandatory to verify that radiotracer uptake is truly within the left ventricular myocardium rather than the cavity blood pool.
- The Non-Invasive Diagnostic Rule (Class I): Perugini Grade 2 or 3 myocardial uptake on SPECT + Negative sFLC, Negative SIFE, and Negative UIFE confirms ATTR Cardiac Amyloidosis with 100% specificity without endomyocardial biopsy.
VISTEP 4: WHEN INVASIVE BIOPSY AND MASS SPECTROMETRY ARE REQUIRED, PLUS TTR GENOTYPING
- Strict Indications for Histological Biopsy (Endomyocardial Biopsy or Surrogate Fat Pad / Bone Marrow Biopsy):
- Scenario A — Positive Monoclonal Protein Screen (Abnormal sFLC, SIFE, or UIFE): Regardless of whether the PYP scan is Grade 0 or Grade 2/3 (since MGUS coexists in 20 to 40 percent of elderly ATTRwt patients, and AL can show Grade 2/3 PYP uptake), histological biopsy with fibril typing is mandatory before starting chemotherapy or TTR stabilizers. (Note: Abdominal fat pad aspirate has ~80–85% sensitivity in systemic AL, ~45–65% in ATTRv, and only ~15% in ATTRwt; therefore, Endomyocardial Biopsy [EMB] is often required when fat pad biopsy is negative.)
- Scenario B — Negative Monoclonal Screen with Equivocal Grade 1 PYP Scan (or Grade 0 PYP scan when high suspicion of rare TTR variants like Phe64Leu/Ser77Tyr or ApoA-I amyloidosis exists).
- Histopathology and Gold-Standard Fibril Typing:
- Congo Red Staining: Demonstrates salmon-pink deposits under light microscopy and pathognomonic apple-green birefringence under cross-polarized light (or Thioflavin T/S fluorescence).
- Laser Microdissection and Liquid Chromatography–Tandem Mass Spectrometry (LMD-LC-MS/MS): The gold standard (near-100 percent specificity) for definitive amyloid precursor protein typing on biopsy tissue (superior to immunohistochemistry, which can yield false results due to serum protein contamination).
- Mandatory TTR Gene Sequencing (Class I in All Confirmed ATTR-CM): Every patient diagnosed with ATTR Cardiac Amyloidosis—regardless of age—must undergo TTR genetic sequencing to differentiate wild-type (ATTRwt) from hereditary/variant (ATTRv) disease, triggering cascade genetic testing of first-degree relatives and unlocking access to TTR gene silencers.
Key references
- Gillmore JD, Maurer MS, Falk RH, et al.: Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis, Circulation, 2016.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al.: Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases, European Heart Journal, 2021.
- Kittleson MM, Ruberg FL, Ambardekar AV, et al.: 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis, Journal of the American College of Cardiology, 2023.
meritmedscript.comDr. Sidhartha Mullapudi
